<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03628001</url>
  </required_header>
  <id_info>
    <org_study_id>1442</org_study_id>
    <nct_id>NCT03628001</nct_id>
  </id_info>
  <brief_title>A Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction</brief_title>
  <official_title>A Prospective, Randomized, Multicenter Study Comparing Sems Placement With and and Without Biliary Sphincterectomy in Patients With Malignant Biliary Obstruction (ES vs noES-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and rationale Placement of biliary self expanding metal stent (SEMS) is indicated&#xD;
      when malignant common bile duct obstruction is encountered.&#xD;
&#xD;
      Currently, there is still controversy regarding the use of endoscopic sphincterotomy (EST)&#xD;
      before the placement of biliary stents. EST may facilitate insertion of self expandable metal&#xD;
      stent (SEMS) and also help avert the development of pancreatitis from stent-related occlusion&#xD;
      of the pancreatic duct. On the other hand, ES is also independently associated with&#xD;
      pancreatitis, bleeding, and perforation.&#xD;
&#xD;
      Latest European guidelines indicate that EST is not necessary for inserting single plastic or&#xD;
      metal biliary stents, nevertheless a more recent meta analysis showed that ES may decrease&#xD;
      the rate of PEP.&#xD;
&#xD;
      Population and patient selection criteria All the patient referred for endoscopic retrograde&#xD;
      cholangiopancreatography (ERCP) due to malignant bile duct obstruction.&#xD;
&#xD;
      Study design and study duration Prospective randomized, multicenter study. 18 months.&#xD;
&#xD;
      Description of study treatment/product/intervention All the patients will be randomly&#xD;
      assigned to undergo ERCP with (Group A) or without (Group B) ES before biliary SEMS&#xD;
      placement.&#xD;
&#xD;
      All the endoscopic procedures will be performed by experienced endoscopist in the endoscopy&#xD;
      suite.&#xD;
&#xD;
      All the procedure will be conducted under deep sedation. SEMS placed will be fully covered.&#xD;
&#xD;
      Objectives To assess the need for EST before SEMS placement in patients with malignant bile&#xD;
      duct obstruction.&#xD;
&#xD;
      To evaluate immediate (periprocedural) and delayed (30 days) post ERCP complications&#xD;
      including pancreatitis, SEMS migration, bleeding and perforation.&#xD;
&#xD;
      Statistical methods, data analysis A sample size analysis to detect superiority at 5%&#xD;
      significance level and a power of 80% showed that 500 patients had to be enrolled in each&#xD;
      group.&#xD;
&#xD;
      Continuous variables such age will be reported in terms of their mean and range, and t-test&#xD;
      will be done to test their main difference.&#xD;
&#xD;
      X square test or Fisher exact test will be carried out for statistical analysis to compare&#xD;
      rates of total complications between the two groups and rates of pancreatitis, bleeding,&#xD;
      stent migration and perforation.&#xD;
&#xD;
      Wilcoxon Mann-Withney test will be used for comparison of means between 2 continuous&#xD;
      variables. A single-tailed P value of less than 0,05 is considered significant.&#xD;
&#xD;
      Study time table Project starting date: 15-7-2015 Project completion of patients accrual:&#xD;
      15-10-2016 Project completion of data collection: 15-11-2016 Project data analysis: 15-2-2017&#xD;
      Project presentation of scientific report: 15-4-2017&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and type of complications after ERCP.</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Bile Duct Obstruction</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ERCP with (Group A) ES before biliary SEMS placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ERCP without (Group B) ES before biliary SEMS placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP</intervention_name>
    <description>Pts will be randomized with or without sphinterectomy.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred for endoscopic retrograde cholangiopancreatography&#xD;
&#xD;
          -  Malignant bile duct obstruction&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide inform consent&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Suspected perforation of the GI tract&#xD;
&#xD;
          -  Anatomical alterations due to previous surgery (Billroth surgery)&#xD;
&#xD;
          -  Coagulation alterations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Anderloni, MD</last_name>
    <phone>0039-02-82247308</phone>
    <email>andrea.anderloni@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Repici, MD</last_name>
    <phone>0039-02-82247493</phone>
    <email>alessandro.repici@hunimed.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy Unit, Gastroenterology Department, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+390282247493</phone>
      <email>alessadro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta Maselli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endoscopic retrograde cholangiopancreatography (ERCP)</keyword>
  <keyword>Distal malignant bile duct obstruction</keyword>
  <keyword>Sphincterotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT03628001/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

